Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 18;10(1):132.
doi: 10.3390/antiox10010132.

Oxidised LDL and Anti-Oxidised LDL Antibodies Are Reduced by Lipoprotein Apheresis in a Randomised Controlled Trial on Patients with Refractory Angina and Elevated Lipoprotein(a)

Tina Z Khan  1   2 , Adam Hartley  3 , Dorian Haskard  3 , Mikhail Caga-Anan  3 , Dudley J Pennell  1   2 , Peter Collins  1   2 , Mahmoud Barbir  2   4 , Ramzi Khamis  3
Affiliations

Oxidised LDL and Anti-Oxidised LDL Antibodies Are Reduced by Lipoprotein Apheresis in a Randomised Controlled Trial on Patients with Refractory Angina and Elevated Lipoprotein(a)

Tina Z Khan et al. Antioxidants (Basel). .

Abstract

Aims: An abundance of epidemiological evidence demonstrates that elevated lipoprotein(a) (Lp(a)) represents a significant contributing risk factor towards the development of cardiovascular disease. In particular, raised Lp(a) may play a mechanistic role in patients with refractory angina. Studies have also shown a correlation between oxidised LDL (oxLDL) levels and atherosclerotic burden as well as rates of cardiovascular events. Antibodies against oxLDL (anti-oxLDL) are involved in the removal of oxLDL. Lipoprotein apheresis (LA), which removes lipoproteins using extra-corporeal processes, is an established means of reducing Lp(a), and thereby reduces cardiovascular events. The aim of this study was to investigate the effect of LA on oxLDL and anti-oxLDL levels amongst those with refractory angina in the context of raised Lp(a). Methods: We performed a sub-study within a randomised controlled crossover trial involving 20 patients with refractory angina and raised Lp(a) > 500 mg/L, comparing the effect of three months of blinded weekly LA or sham, followed by crossover to the opposite study arm. We utilized enzyme-linked immunosorbent assays (ELISA) to quantify oxLDL and IgG/ IgM anti-oxLDL antibody levels at baseline and following three months of active LA or sham sessions. Results: Following three months of LA, there was a 30% reduction in oxLDL from 0.37 ± 0.06 to 0.26 ± 0.04 with a mean drop of -0.11 units (U) (95% CI -0.13, -0.09) compared to no significant change with sham therapy (p < 0.0001 between treatment arms). LA also led to a 22% reduction in levels of IgG and IgM anti-oxLDL, again with no significant change demonstrated during sham (p = 0.0036 and p = 0.012, respectively, between treatment arms). Conclusion: Amongst patients with refractory angina in the context of elevated Lp(a), LA significantly lowers levels of oxLDL and anti-oxLDL antibodies, representing potential mechanisms by which LA yields symptomatic and prognostic benefits in this patient cohort.

Keywords: lipoprotein apheresis; lipoprotein(a); oxidised LDL.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart summarising the trial methodology.
Figure 2
Figure 2
CONSORT flow chart.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Khan T.Z., Pottle A., Pennell D.J., Barbir M.S. The impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a): Objectives and methods of a randomised controlled trial. Atheroscler. Suppl. 2015;18:103–108. doi: 10.1016/j.atherosclerosissup.2015.02.019. - DOI - PubMed
    1. Borberg H. Comparison of different Lp(a) elimination techniques: A retrospective evaluation. Trans. Apheres. Sci. 2009;41:61–65. doi: 10.1016/j.transci.2009.05.014. - DOI - PubMed
    1. Tsimikas S., Brilakis E.S., Miller E.R., McConnell J.P., Lennon R.J., Kornman K.S., Witztum J.L., Berger P.B. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N. Engl. J. Med. 2005;353:46–57. doi: 10.1056/NEJMoa043175. - DOI - PubMed
    1. Matsuo Y., Kubo T., Okumoto Y., Ishibashi K., Komukai K., Tanimoto T., Ino Y., Kitabata H., Hirata K., Imanishi T., et al. Circulating malondialdehyde-modified low-density lipoprotein levels are associated with the presence of thin-cap fibroatheromas determined by optical coherence tomography in coronary artery disease. Eur. Heart J. Cardiovasc. Imag. 2013;14:43–50. doi: 10.1093/ehjci/jes094. - DOI - PubMed
    1. Ehara S., Ueda M., Naruko T., Haze K., Itoh A., Otsuka M., Komatsu R., Matsuo T., Itabe H., Takano T., et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103:1955–1960. doi: 10.1161/01.CIR.103.15.1955. - DOI - PubMed

LinkOut - more resources